Want to see AU:PAR full AI Analyst Report?

Paradigm Biopharmaceuticals (PAR) Price & Analysis

46 Followers

PAR Stock Chart & Stats

AU$0.22

<AU$0.01(3.03%)

At close: Jul 27 4:00 PM EDT

AU$0.22

<AU$0.01(3.03%)

Day’s Range― - ―

52-Week RangeAU$0.14 - AU$0.47

Previous CloseN/A

Volume999.53K

Average Volume (3M)3.03M

Market Cap

AU$153.48M

Enterprise ValueAU$48.90

Total Cash (Recent Filing)AU$15.44M

Total Debt (Recent Filing)AU$7.51M

Price to Earnings (P/E)―

Beta2.43

Next Earnings

Feb 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding626,433,350

10 Day Avg. Volume2,323,361

30 Day Avg. Volume3,032,084

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)17.59

Price to Sales (P/S)761.77

P/FCF Ratio-1.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.42

Price Target Upside90.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.08

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe reported revenue growth indicates that the company has expanded its top line despite its small and volatile revenue base. If this growth can be sustained, it could improve operating scale, support broader commercial adoption, and provide a foundation for future margin improvement.

Growing Asset BaseAn increase in total assets suggests that the company continued building its resource base during 2026. While asset growth has not yet translated into profitability, a larger operating base may support development and commercial activities if management can deploy capital more efficiently over time.

Lower Cash BurnThe reduction in free cash flow outflows compared with 2024 represents some improvement in cash consumption. Although operations remain far from self-funding, a sustained moderation in burn would extend financial runway and reduce the pace at which the company needs additional external capital.

Bears Say

Persistent UnprofitabilityPersistent losses and recurring negative gross profit show that the business has not established a stable, profitable operating model. Losses that remain large relative to revenue can consume capital, limit reinvestment capacity, and make future profitability dependent on significant improvement in scale or cost structure.

Negative Cash GenerationConsistently negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. Continued cash burn can require repeated financing, increase dilution or funding pressure, and restrict the resources available for development and commercial execution.

Rising LeverageThe sharp move from near-zero leverage to roughly 2.16 times debt-to-equity materially weakens financial flexibility. Higher debt alongside reduced equity increases exposure to financing costs and capital needs, while cumulative losses leave a smaller balance-sheet buffer to absorb further setbacks.

Paradigm Biopharmaceuticals News

Paradigm Biopharmaceuticals Shares Suspended as ASX Flags Financial Breach

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has had its securities suspended from quotation...

10h ago

Paradigm Biopharmaceuticals Enters Voluntary Administration

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals Limited has entered voluntary administration after its...

10h ago

Paradigm Extends Trading Suspension Pending Phase 3 Data Review

An update from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has requested a continuation of...

2d ago

Paradigm Biopharmaceuticals Cancels 2 Million Convertible Notes

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals Limited has announced the cessation...

6d ago

Paradigm Returns US$2m to Obsidian Amid Phase 3 Trial Review

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has agreed to return US$2 million received...

6d ago

Paradigm Biopharmaceuticals Halts Trading Pending Phase 3 Trial Update

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has requested and received a voluntary suspension...

7d ago

Paradigm Biopharmaceuticals Halts Trading Ahead of Phase 3 Trial Update

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has requested a trading halt in its...

9d ago

Paradigm Biopharmaceuticals Seeks Quotation for 600,000 New ASX Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

12d ago

Paradigm Biopharmaceuticals reshapes medical leadership as Phase 3 osteoarthritis trial advances

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has appointed Dr Daniel Furtner...

15d ago

Paradigm Biopharmaceuticals Lists Additional Shares on ASX

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals Limited has applied for quotation...

16d ago

PAR FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.14 and its highest was AU$0.47 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is AU$153.48M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 147 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.096 earnings per share for the quarter.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 626,433,350 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.096 in its last earnings report. Following the earnings report the stock price went up 5%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:PAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

31.46%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.

Paradigm Biopharmaceuticals (PAR) Earnings & Revenues

Historic Earnings Reports

PAR Stock 12 Month Forecast

Average Price Target

AU$0.42

▲(90.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.205,0.22153846153846152,0.23807692307692307,0.2546153846153846,0.27115384615384613,0.2876923076923077,0.3042307692307692,0.32076923076923075,0.3373076923076923,0.3538461538461538,0.3703846153846153,0.3869230769230769,0.4034615384615384,{"y":0.42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.205,0.22153846153846152,0.23807692307692307,0.2546153846153846,0.27115384615384613,0.2876923076923077,0.3042307692307692,0.32076923076923075,0.3373076923076923,0.3538461538461538,0.3703846153846153,0.3869230769230769,0.4034615384615384,{"y":0.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.205,0.22153846153846152,0.23807692307692307,0.2546153846153846,0.27115384615384613,0.2876923076923077,0.3042307692307692,0.32076923076923075,0.3373076923076923,0.3538461538461538,0.3703846153846153,0.3869230769230769,0.4034615384615384,{"y":0.42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.335,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.425,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.295,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.255,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.16,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.155,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.165,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.205,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >